Edge Therapeutics, a US-based biopharmaceutical company incubated at the New Jersey Institute of Technology, has raised $18m in its series C round.
Investment bank Maxim Group was the placement agent and financial adviser for the offering, which will fund a phase II study of its lead product candidate, EG-1962 (nimodipine microparticles), for the prevention of complications from bleeding.
In October 2010, the New Jersey Technology Council named Edge one of its four “incubator companies to watch”.
